Literature DB >> 22987342

Severe hyperglycemia immediately after allogeneic hematopoietic stem-cell transplantation is predictive of acute graft-versus-host disease.

Efrem Gebremedhin1, Carolyn E Behrendt, Ryotaro Nakamura, Pablo Parker, Behrouz Salehian.   

Abstract

Stress hyperglycemia and acute graft-versus-host disease (GVHD), the major early complication of hematopoietic stem cell transplantation (HSCT), are both associated with excessive release of inflammatory cytokines. We investigated whether new-onset hyperglycemia immediately after HSCT predicts acute GVHD. We studied nondiabetic adult recipients of human leukocyte antigen-matched HSCT (peripheral blood stem cells) for acute leukemia. Using mean morning serum glucose on Days 1-10, we classified hyperglycemia as: mild (6.11-8.33 mmol/L), moderate (8.34-9.98), and severe (minimum of 9.99). Subjects who were GVHD-free on Day 10 were followed during Days 11-100 for grades II-IV acute GVHD or competing event. Evaluation utilized cumulative incidence-based proportional hazards regression. Subjects (n = 328) were age 18-74, median of 49 years. Per body mass index (BMI)--25.0 % were obese (BMI, 30-48), 33.8 % overweight (25 to <30), 30.8 % normal weight (21 to <25), and 10.4 % lean (18 to <21). Mild, moderate, or severe hyperglycemia occurred during Days 1-10 in 50.0, 21.3, and 16.8 % of subjects, respectively. Cumulative incidence on Day 100 was 44.8 (±2.8) % acute GVHD and 7.9 (±1.5) % competing event. Among normal-to-overweight subjects (n = 212), severe hyperglycemia developed in 14.2 % (n = 30) and more than doubled the risk of acute GVHD (hazards ratio, 2.71; 95 % CI, 1.58-4.65--adjusted for donor/recipient characteristics, prophylactic regimen, and mucositis). In contrast, among obese subjects (n = 82), severe hyperglycemia developed in 30.5 % (n = 25) but did not significantly affect risk of GVHD. (No lean subjects (n = 34) developed severe hyperglycemia.) Hyperglycemia that was less than severe had an effect indistinguishable from normoglycemia. In nondiabetic patients, severe hyperglycemia immediately after allogeneic HSCT indicates increased likelihood of acute GVHD. This association is absent in obese patients, who may be primed by obesity-induced inflammation to develop severe hyperglycemia even without experiencing the cytokine storm that is essential to GVHD pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22987342      PMCID: PMC3546172          DOI: 10.1007/s10753-012-9533-7

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  32 in total

1.  Secondary diabetes associated with 5-fluorouracil-based chemotherapy regimens in non-diabetic patients with colorectal cancer: results from a single-centre cohort study.

Authors:  J-P Feng; X-L Yuan; M Li; J Fang; T Xie; Y Zhou; Y-M Zhu; M Luo; M Lin; D-W Ye
Journal:  Colorectal Dis       Date:  2013-01       Impact factor: 3.788

2.  A Biometric Study of Human Basal Metabolism.

Authors:  J A Harris; F G Benedict
Journal:  Proc Natl Acad Sci U S A       Date:  1918-12       Impact factor: 11.205

3.  The incidence and impact of dextrose dose on hyperglycemia from parenteral nutrition (PN) exposure in hematopoietic stem cell transplant (HSCT) recipients.

Authors:  Patricia Sheean; Carol Braunschweig
Journal:  JPEN J Parenter Enteral Nutr       Date:  2006 Jul-Aug       Impact factor: 4.016

4.  Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines.

Authors:  G R Hill; J M Crawford; K R Cooke; Y S Brinson; L Pan; J L Ferrara
Journal:  Blood       Date:  1997-10-15       Impact factor: 22.113

5.  Hyperacute GVHD: risk factors, outcomes, and clinical implications.

Authors:  Rima M Saliba; Marcos de Lima; Sergio Giralt; Borje Andersson; Issa F Khouri; Chitra Hosing; Shubhra Ghosh; Joyce Neumann; Yvonne Hsu; Jorge De Jesus; Muzaffar H Qazilbash; Richard E Champlin; Daniel R Couriel
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

6.  Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) in adults.

Authors:  Willis H Navarro; Manza-A Agovi; Brent R Logan; Karen Ballen; Brian J Bolwell; Haydar Frangoul; Vikas Gupta; Theresa Hahn; Vincent T Ho; Mark Juckett; Hillard M Lazarus; Mark R Litzow; Jane L Liesveld; Jan S Moreb; David I Marks; Philip L McCarthy; Marcelo C Pasquini; J Douglas Rizzo
Journal:  Biol Blood Marrow Transplant       Date:  2010-04-20       Impact factor: 5.742

7.  Reduced incidence of acute graft versus host disease (GVHD) of the gut in Chinese carriers of Helicobacter pylori during allogeneic bone marrow transplantation.

Authors:  W Y Au; R W M Wong; B C Y Wong; A K W Lie; R Liang; A Y H Leung; Y-L Kwong
Journal:  Ann Hematol       Date:  2003-10-10       Impact factor: 3.673

8.  Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia.

Authors:  Theresa Hahn; Philip L McCarthy; Mei-Jie Zhang; Dan Wang; Mukta Arora; Haydar Frangoul; Robert Peter Gale; Gregory A Hale; John Horan; Luis Isola; Richard T Maziarz; Jon J van Rood; Vikas Gupta; Joerg Halter; Vijay Reddy; Pierre Tiberghien; Mark Litzow; Claudio Anasetti; Stephen Pavletic; Olle Ringdén
Journal:  J Clin Oncol       Date:  2008-11-03       Impact factor: 44.544

Review 9.  Drug-induced disorders of glucose tolerance.

Authors:  M K Pandit; J Burke; A B Gustafson; A Minocha; A N Peiris
Journal:  Ann Intern Med       Date:  1993-04-01       Impact factor: 25.391

10.  Radiation-induced acute necrosis of the pancreatic islet and the diabetic syndrome in th golden hamster (Mesocricetus auratus).

Authors:  S Tsubouchi; H Suzuki; H Ariyoshi; T Matsuzawa
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1981-07
View more
  14 in total

Review 1.  Measurement of Hyperglycemia and Impact on Health Outcomes in People With Cancer: Challenges and Opportunities.

Authors:  Susan Storey; Diane Von Ah; Marilyn J Hammer
Journal:  Oncol Nurs Forum       Date:  2017-07-01       Impact factor: 2.172

Review 2.  Hyperglycemia in patients with hematologic malignancies.

Authors:  Sara J Healy; Kathleen M Dungan
Journal:  Curr Diab Rep       Date:  2015-03       Impact factor: 4.810

3.  Dynamic change of glycemic status during the early phase after allogeneic hematopoietic stem cell transplantation.

Authors:  S Fuji; K Yakushijin; S-W Kim; K Yoshimura; S Kurosawa; T Fukuda
Journal:  Bone Marrow Transplant       Date:  2015-07-13       Impact factor: 5.483

4.  Clinical impact of hyperglycemia on days 0-7 after allogeneic stem cell transplantation.

Authors:  A Kawajiri; S Fuji; Y Tanaka; C Kono; T Hirakawa; T Tanaka; R Ito; Y Inoue; K Okinaka; S Kurosawa; Y Inamoto; S-W Kim; T Yamashita; T Fukuda
Journal:  Bone Marrow Transplant       Date:  2017-03-20       Impact factor: 5.483

5.  Malglycemia is associated with poor outcomes in pediatric and adolescent hematopoietic stem cell transplant patients.

Authors:  Jenna Sopfe; Laura Pyle; Amy K Keating; Kristen Campbell; Arthur K Liu; R Paul Wadwa; Michael R Verneris; Roger H Giller; Gregory P Forlenza
Journal:  Blood Adv       Date:  2019-02-12

Review 6.  How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT.

Authors:  S Fuji; A Rovó; K Ohashi; M Griffith; H Einsele; M Kapp; M Mohty; N S Majhail; B G Engelhardt; A Tichelli; B N Savani
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

7.  Pre-transplant diabetes mellitus is a risk factor for non-relapse mortality, especially infection-related mortality, after allogeneic hematopoietic SCT.

Authors:  K Takano; S Fuji; N Uchida; H Ogawa; K Ohashi; T Eto; H Sakamaki; Y Morishima; K Kato; R Suzuki; T Fukuda
Journal:  Bone Marrow Transplant       Date:  2015-01-26       Impact factor: 5.483

8.  Prevalence, predictors, and outcomes of steroid-induced hyperglycemia in hospitalized patients with hematologic malignancies.

Authors:  Sara J Healy; Haikady N Nagaraja; Dhuha Alwan; Kathleen M Dungan
Journal:  Endocrine       Date:  2017-01-06       Impact factor: 3.633

Review 9.  Biomarkers for Early Complications After Hematopoietic Stem Cell Transplantation.

Authors:  Courtney M Rowan; Sophie Paczesny
Journal:  Clin Lab Med       Date:  2018-12-18       Impact factor: 1.935

10.  Blood glucose control using a computer-guided glucose management system in allogeneic hematopoietic cell transplant recipients.

Authors:  C Espina; I Jenkins; L Taylor; R Farah; E Cho; J Epworth; K Coleman; J Pinelli; S Mentzer; L Jarrett; T Gooley; P O'Donnell; I B Hirsch; M Bar
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.